Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of IGG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and incidents via the mucosa

Use of IGG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and incidents via the mucosa

US Patent 9822185 · Granted Nov 21, 2017

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Method for reducing the trisulfide level in proteins2022
Reduction of in vitro genotoxicity of pollen extracts by removal of flavonoids2021
Reduction of in vitro genotoxicity of pollen extracts by removal of flavonoids2021
IL-10 as a predictive biomarker of responsiveness to house dust mite allergen im2021
IL-10 as a predictive biomarker of responsiveness to house dust mite allergen im2021
Markers of immune response2021
Markers of immune response2021
Markers of immune response2021
Sialylated fetuin-A as a marker of immunotherapy efficacy2021
Sialylated fetuin-A as a marker of immunotherapy efficacy2021
Method for increasing the glutathione level in cells2020
Compositions for antigen-specific induction of tolerance2020